PLEASANTON, Calif.--(BUSINESS WIRE)--NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced its sponsorship of the fourth annual “Drive for Men’s Health” event. Funds raised by the Drive for Men’s Health will be donated to Florida Polytechnic University and Cochrane Urology, a division of Cochrane Collaboration, a global independent network of researchers, professionals, patients, and caregivers working to produce credible, accessible health information that is recognized as the gold standard for trusted research and information.
Timed to coincide with National Men’s Health week, the Drive for Men’s Health is designed to increase awareness of men’s health issues and to encourage men to make their health a priority. During the Drive, Jamin Brahmbhatt, M.D., and Sijo Parekattil, M.D., co-directors of The PUR (Personalized Urology & Robotics) Clinic at South Lake Hospital, in affiliation with Orlando Health, will climb into a blue and white Tesla Model S and embark on a 3,500 mile cross-country journey beginning in Florida on June 3 and ending in Utah, via New Orleans, Houston, and Los Angeles. Throughout the journey, the drivers will make stops that will feature speakers, events and educational activities to raise awareness about men’s health. The drive will conclude with a 5k run/walk in Salt Lake City on June 10.
“We are thrilled to support the Drive for Men’s Health once again,” said Dave Amerson, president and CEO of NeoTract. “Drs. Brahmbhatt and Parekattil’s commitment to raising awareness about men’s health issues inspires men to take more care with their health. Their efforts help to dispel myths about urological health conditions and encourage men to see their doctor. In the case of benign prostatic hyperplasia, or BPH, many men may assume symptoms are an inevitable part of aging. Education is the key to getting men to see their doctors sooner and more frequently to prevent a common problem from becoming more serious.”
In 2016, the Drive for Men’s Health reached more than 300 million people through news stories, live appearances on local news, live streaming from the road, call-in radio shows, and social media in addition to their scheduled stops. This year, urologists Lance Walsh, M.D., Ph.D., Steven Gange, M.D. FACS, and Gregg Eure, M.D., FACS will be talking via webcast during the Drive about BPH symptoms and the UroLift System as a minimally invasive treatment option.
“NeoTract is an important and valued sponsor for the Drive for Men’s Health. The UroLift System provides a proven minimally invasive option for men suffering from enlarged prostate,” said Dr. Sijo Parekattil, urologic surgeon and co-founder of the PUR clinic. “Part of our mission is to educate men and their partners that there are safe and simple procedures such as the UroLift System available to them. Our mission is closely aligned with the work of NeoTract and their involvement enables us to educate and encourage men to see their doctors.”
Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia. The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.